Fmr LLC Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Fmr LLC increased its position in 10x Genomics, Inc. (NASDAQ:TXG) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,454,434 shares of the company’s stock after buying an additional 86,455 shares during the period. Fmr LLC owned 11.11% of 10x Genomics worth $193,206,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in 10x Genomics by 70.1% during the 4th quarter. Russell Investments Group Ltd. now owns 16,818 shares of the company’s stock valued at $242,000 after purchasing an additional 6,932 shares during the last quarter. Grant Private Wealth Management Inc purchased a new stake in shares of 10x Genomics in the fourth quarter worth approximately $209,000. Bryce Point Capital LLC bought a new stake in shares of 10x Genomics during the 4th quarter worth approximately $448,000. Trexquant Investment LP boosted its holdings in 10x Genomics by 196.2% during the 4th quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock valued at $8,539,000 after acquiring an additional 393,854 shares during the period. Finally, National Bank of Canada FI bought a new position in 10x Genomics in the 4th quarter valued at $1,518,000. 84.68% of the stock is owned by institutional investors.

Insider Transactions at 10x Genomics

In other news, Director Alan Mateo bought 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares of the company’s stock, valued at $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. UBS Group dropped their price objective on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Barclays decreased their price objective on 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday. Citigroup dropped their target price on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Finally, Leerink Partnrs downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $19.79.

10x Genomics Price Performance

Shares of TXG opened at $8.01 on Friday. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $36.15. The stock has a market cap of $979.64 million, a PE ratio of -5.27 and a beta of 2.01. The firm has a fifty day moving average price of $10.44 and a 200 day moving average price of $13.96.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.